规格 | 价格 | 库存 | 数量 |
---|---|---|---|
5mg |
|
||
10mg |
|
||
50mg |
|
||
100mg |
|
||
250mg |
|
||
500mg |
|
||
Other Sizes |
|
靶点 |
VEGFR3 (IC50 = 1 nM); VEGFR1 (IC50 = 2 nM); CSF1R (IC50 = 4 nM); FGFR1 (IC50 = 15 nM); VEGFR2 (IC50 = 24 nM)
|
---|---|
体外研究 (In Vitro) |
SuLfatinib 可有效抑制 HEK293KDR 细胞中 VEGF 诱导的 VEGFR2 磷酸化和 RAW264.7 细胞中 CSF1 刺激的 CSF1R 磷酸化,IC50 分别为 2 和 24。它还抑制 FGFR1、CSF1R 和 VEGFR1、2 和 3. 79 纳米的突变。此外,SuLfatinib 抑制 VEGF 或 FGF 诱导的 HUVEC 细胞生长的 IC50<50 nM [1]。此外,在 CHO 细胞中,它的 IC50 为 6.8 μM,使其成为 hERG 的兄弟 [2]。
|
体内研究 (In Vivo) |
在动物实验中,裸鼠肺组织中 VEGF 刺激的 VEGFR2 磷酸化受到单次 SuLfatinib 的调节。此外,24 小时后 24 个通道中 FGF23 水平的升高表明 FGFR 受体信号传导受到抑制。通过 VEGFR 和 FGFR 信号传导强烈抑制血管生成,如在几种人类异种移植模型中显示的严重生长抑制和 CD31 肿瘤表达的显着减少所表明的那样。在同基因肿瘤模型 CT-26 中,索凡替尼在单一药物治疗后显示出肿瘤发展的适度减少[1]。小鼠体内的 AUC 和 Cmax 分别为 397 ng/mL 和 138 ng/mL,侧壁厚度为 10 mg/kg [1]。
|
酶活实验 |
Z-lyte 检测试剂盒用于评估 KDR 激酶的抑制活性。测试化合物索凡替尼以不同浓度存在于 384 孔板中,测试系统中还含有 300 ng/mL 重组人 KDR 催化结构域、10 μM ATP 和 1 μM 底物肽。总体积为 10 μL。在室温 (25°C) 摇床上放置一小时后,酶抑制过程继续进行。为了停止反应,添加 5 μL 终止液[2]。
|
动物实验 |
Male ICR mice (n = 6 per group; weight 20–30 g) are used to study the phamacokinetics of sulfatinib following a single intravenous and oral dose of 2.5 and 10 mg/kg, respectively. Sulfatinib is dissolved in DMSO (0.25%)-solutol (10%)-ethanol (10%)-physiological saline (797.75%) at a concentration of 0.25 mg/mL for intravenous dosing formulation. Additionally, 0.5% CMC-Na is used to prepare the p.o. Dosing formulation (1 mg/mL). Following intravenous or PO dosage, blood is drawn via the ophthalmic vein at 0 (pre-close), 5, 15, 30 minutes, and 1, 1.5, 2, 4, 8, and 24 hours. The blood is then anticoagulated using heparin-Na. Following centrifugation, plasma samples are separated, and protein is precipitated using an internal standard containing acetonitrilel[2].
|
参考文献 |
[1]. PCT Int. Appl. (2011), WO 2011060746 A1 20110526
|
分子式 |
C24H28N6O3S
|
---|---|
分子量 |
480.587
|
精确质量 |
480.1944
|
元素分析 |
C, 59.98; H, 5.87; N, 17.49; O, 9.99; S, 6.67
|
CAS号 |
1308672-74-3
|
相关CAS号 |
1308672-74-3;1816307-67-1
|
外观&性状 |
Solid powder
|
SMILES |
CC1=CC2=C(N1)C=CC(=C2)OC3=NC(=NC=C3)NC4=CC=CC(=C4)CS(=O)(=O)NCCN(C)C
|
InChi Key |
TTZSNFLLYPYKIL-UHFFFAOYSA-N
|
InChi Code |
InChI=1S/C24H28N6O3S/c1-17-13-19-15-21(7-8-22(19)27-17)33-23-9-10-25-24(29-23)28-20-6-4-5-18(14-20)16-34(31,32)26-11-12-30(2)3/h4-10,13-15,26-27H,11-12,16H2,1-3H3,(H,25,28,29)
|
化学名 |
N-[2-(dimethylamino)ethyl]-1-[3-[[4-[(2-methyl-1H-indol-5-yl)oxy]pyrimidin-2-yl]amino]phenyl]methanesulfonamide
|
别名 |
HMPL012; HMPL012; HMPL 012; surufatinib; Sulfatinib
|
HS Tariff Code |
2934.99.9001
|
存储方式 |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
运输条件 |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
溶解度 (体外) |
DMSO: ~96 mg/mL (~199.8 mM)
|
---|---|
溶解度 (体内) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (4.33 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (4.33 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C,1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.08 mg/mL (4.33 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. 1、请先配制澄清的储备液(如:用DMSO配置50 或 100 mg/mL母液(储备液)); 2、取适量母液,按从左到右的顺序依次添加助溶剂,澄清后再加入下一助溶剂。以 下列配方为例说明 (注意此配方只用于说明,并不一定代表此产品 的实际溶解配方): 10% DMSO → 40% PEG300 → 5% Tween-80 → 45% ddH2O (或 saline); 假设最终工作液的体积为 1 mL, 浓度为5 mg/mL: 取 100 μL 50 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中,混合均匀/澄清;向上述体系中加入50 μL Tween-80,混合均匀/澄清;然后继续加入450 μL ddH2O (或 saline)定容至 1 mL; 3、溶剂前显示的百分比是指该溶剂在最终溶液/工作液中的体积所占比例; 4、 如产品在配制过程中出现沉淀/析出,可通过加热(≤50℃)或超声的方式助溶; 5、为保证最佳实验结果,工作液请现配现用! 6、如不确定怎么将母液配置成体内动物实验的工作液,请查看说明书或联系我们; 7、 以上所有助溶剂都可在 Invivochem.cn网站购买。 |
制备储备液 | 1 mg | 5 mg | 10 mg | |
1 mM | 2.0808 mL | 10.4039 mL | 20.8078 mL | |
5 mM | 0.4162 mL | 2.0808 mL | 4.1616 mL | |
10 mM | 0.2081 mL | 1.0404 mL | 2.0808 mL |
1、根据实验需要选择合适的溶剂配制储备液 (母液):对于大多数产品,InvivoChem推荐用DMSO配置母液 (比如:5、10、20mM或者10、20、50 mg/mL浓度),个别水溶性高的产品可直接溶于水。产品在DMSO 、水或其他溶剂中的具体溶解度详见上”溶解度 (体外)”部分;
2、如果您找不到您想要的溶解度信息,或者很难将产品溶解在溶液中,请联系我们;
3、建议使用下列计算器进行相关计算(摩尔浓度计算器、稀释计算器、分子量计算器、重组计算器等);
4、母液配好之后,将其分装到常规用量,并储存在-20°C或-80°C,尽量减少反复冻融循环。
计算结果:
工作液浓度: mg/mL;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL)。如该浓度超过该批次药物DMSO溶解度,请首先与我们联系。
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL ddH2O,混匀澄清。
(1) 请确保溶液澄清之后,再加入下一种溶剂 (助溶剂) 。可利用涡旋、超声或水浴加热等方法助溶;
(2) 一定要按顺序加入溶剂 (助溶剂) 。
NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
NCT05077384 | Recruiting | Drug: Surufatinib | Neuroendocrine Tumors Non-hematologic Malignancy |
Hutchison Medipharma Limited | September 2, 2021 | Phase 1 Phase 2 |
NCT04579679 | Active Recruiting |
Drug: Surufatinib | Neuroendocrine Tumours Small Intestinal NET |
Hutchmed | August 13, 2021 | Phase 2 |
NCT05171439 | Recruiting | Drug: Surufatinib | Hepatocellular Carcinoma | he Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School |
March 1, 2022 | Phase 2 |
NCT05590572 | Not yet recruiting | Drug: Sulfatinib Drug: Etoposide |
Osteosarcoma | Second Affiliated Hospital, School of Medicine, Zhejiang University |
January 2023 | Phase 1 Phase 2 |
NCT02549937 | Active Recruiting |
Drug: surufatinib | Tumors | Hutchison Medipharma Limited | November 2015 | Phase 1 Phase 2 |